Collapse all
The Business Model Canvas reveals a high-barrier pharmaceutical play that shifts UDCA from a chronic liver treatment to an acute surgical prophylaxis. Success depends on clinical validation and integration into surgical workflows rather than broad consumer adoption.
4 Pharmaceutical Manufacturers Partners like Pfizer to produce medical-grade UDCA in specific perioperative dosages and delivery formats. Academic Medical Centers Institutions like Mayo Clinic to conduct clinical trials and establish the gold-standard dosing protocol. Regulatory Bodies FDA/EMA for securing a new indication for UDCA specifically for renal IRI prophylaxis. Medical Societies The National Kidney Foundation to advocate for the inclusion of UDCA in surgical guidelines. 3 Clinical Trial Management Designing and executing trials to prove the reduction of post-surgical kidney failure via PPARγ activation. Dosing Protocol Optimization Determining the precise timing and concentration of UDCA administration before and after renal surgery. Regulatory Filing Navigating the pathway for a new medical indication for an existing pharmaceutical compound. 3 Clinical Data Proprietary evidence linking E. limosum-derived UDCA levels to reduced renal IRI severity. Medical Expertise Specialized nephrologists and surgeons to lead the implementation of the prophylaxis kit. IP and Patents Patents covering the specific perioperative dosing regimen and kit formulation. 3 Reduced Post-Op Complications Prevents renal ischemia-reperfusion injury, reducing the risk of acute kidney injury (AKI) after surgery. Metabolic Protection Increases fatty acid oxidation and ATP production in proximal tubular epithelial cells to maintain organ function. Standardized Care Kit Provides surgeons with a ready-to-use, medical-grade dosing kit, removing the guesswork from prophylaxis. 2 Clinical Partnerships Deep integration with surgical departments to ensure the kit is part of the standard pre-op checklist. Evidence-Based Trust Maintaining credibility through peer-reviewed publications and transparent trial results. 3 Hospital Procurement Direct sales to hospital pharmacy departments and surgical centers. Medical Conferences Presenting results at nephrology and urology symposiums to drive adoption. Pharmaceutical Distributors Using established B2B medical supply chains to deliver kits to clinics. 3 Nephrologists Specialists managing the post-operative recovery and kidney health of surgical patients. Urological Surgeons The primary users who administer the prophylaxis during the perioperative window. Tertiary Care Hospitals High-volume surgical centers (e.g., Mayo Clinic) performing complex renal procedures. 3 R&D and Clinical Trials High upfront costs for multi-center trials to prove efficacy and safety. Manufacturing and Sterilization Costs associated with producing medical-grade UDCA in a sterile, kit-based format. Regulatory Compliance Fees and legal costs associated with FDA/EMA approval for a new indication. 2 Per-Kit Sale A one-time fee per surgical patient for the complete perioperative UDCA dosing kit. Licensing Agreements Licensing the dosing protocol and IP to larger pharmaceutical firms for global distribution. Necessary to map how the kit is delivered to surgical centers and how value is captured from providers like the Mayo Clinic. · Generated 2026-08-18 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated